<DOC>
	<DOCNO>NCT01796301</DOCNO>
	<brief_summary>This multi-center , randomize , open-label , TPTD-controlled study postmenopausal woman osteoporosis high risk fracture .</brief_summary>
	<brief_title>An Open-label Study Evaluate Effect Treatment With AMG 785 Teriparatide Postmenopausal Women ( STRUCTURE )</brief_title>
	<detailed_description>This multi-center , randomize , open-label , TPTD-controlled study postmenopausal woman osteoporosis high risk fracture .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman , age ≥ 60 ≤ 90 . Received oral bisphosphonate therapy least 3 year immediately prior screen BMD Tscore ≤ 2.50 lumbar spine , total hip femoral neck History nonvertebral fracture age 50 , vertebral fracture . Use agent affect bone metabolism include Strontium ranelate , fluoride ( osteoporosis ) , odanacatib ( MK0822 ) cathepsin K inhibitor , IV bisphosphonates , Denosumab , TPTD PTH analog , Systemic oral transdermal estrogen , SERMs , activate vitamin D3 , vitamin K2 , calcitonin , Tibolone , cinacalcet , Systemic glucocorticosteroids : History metabolic bone disease ( except osteoporosis ) may interfere interpretation study result , sclerosteosis , Paget 's disease , rheumatoid arthritis , osteomalacia , osteogenesis imperfecta , osteopetrosis , ankylose spondylitis , Cushing 's disease , hyperprolactinemia , malabsorption syndrome Vitamin D insufficiency , define 25 ( OH ) vitamin D level &lt; 20 ng/mL , determine central laboratory . Current hyper hypocalcemia Current , uncontrolled hyper hypothyroidism</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>